SLLN-15 

SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC)^[1].

SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner^[1].
SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines^[1].
Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases^[1].
Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

507.35

C₁₉H₂₃N₇Se₂

2403650-93-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chang CH, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019 Mar 1:1-15.  [Content Brief]